Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2006 3
2008 1
2009 6
2010 1
2011 6
2012 7
2013 6
2014 5
2015 7
2016 10
2017 9
2018 17
2019 17
2020 12
2021 15
2022 18
2023 12
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R, Mirtti T, Kilpeläinen TP, Tolonen T, Räisänen-Sokolowski A, Nordling S, Hannus J, Laurila M, Taari K, Tammela TLJ, Autio R, Natunen K, Auvinen A, Rannikko A. Hietikko R, et al. Among authors: rannikko a. World J Urol. 2024 Apr 6;42(1):217. doi: 10.1007/s00345-024-04898-2. World J Urol. 2024. PMID: 38581590 Free PMC article.
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Natunen K, Nevalainen J, Raitanen J, Ronkainen J, van der Kwast T, Riikonen J, Pétas A, Matikainen M, Taari K, Kilpeläinen T, Rannikko AS; ProScreen Trial Investigators. Auvinen A, et al. Among authors: rannikko as. JAMA. 2024 May 7;331(17):1452-1459. doi: 10.1001/jama.2024.3841. JAMA. 2024. PMID: 38581254 Clinical Trial.
PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
Englman C, Maffei D, Allen C, Kirkham A, Albertsen P, Kasivisvanathan V, Baroni RH, Briganti A, De Visschere P, Dickinson L, Gómez Rivas J, Haider MA, Kesch C, Loeb S, Macura KJ, Margolis D, Mitra AM, Padhani AR, Panebianco V, Pinto PA, Ploussard G, Puech P, Purysko AS, Radtke JP, Rannikko A, Rastinehad A, Renard-Penna R, Sanguedolce F, Schimmöller L, Schoots IG, Shariat SF, Schieda N, Tempany CM, Turkbey B, Valerio M, Villers A, Walz J, Barrett T, Giganti F, Moore CM. Englman C, et al. Among authors: rannikko a. Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024.03.014. Online ahead of print. Eur Urol. 2024. PMID: 38556436 Free article.
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
Löffeler S, Bertilsson H, Müller C, Aas K, Haugnes HS, Aksnessæther B, Pesonen M, Thon K, Tandstad T, Murtola T, Poulsen MH, Nordstrøm T, Vigmostad MN, Ottosson F, Holmsten K, Christiansen O, Slaaen M, Haug ES, Storås AH, Asphaug L, Rannikko A, Brasso K; Scandinavian Prostate Cancer Group (SPCG) and the Norwegian Get‐Randomized (GRand) Initiative. Löffeler S, et al. Among authors: rannikko a. BJU Int. 2024 Jun;133(6):680-689. doi: 10.1111/bju.16314. Epub 2024 Mar 12. BJU Int. 2024. PMID: 38469686 Clinical Trial.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Shore ND, et al. Among authors: rannikko a. Oncologist. 2024 Feb 23:oyae019. doi: 10.1093/oncolo/oyae019. Online ahead of print. Oncologist. 2024. PMID: 38394384 Free article.
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Supiot S, Lantz A, Ganguli A, Ivanova J, Kral P, Huang SP, Saad F, Shore ND. Freedland SJ, et al. Among authors: rannikko a. NEJM Evid. 2023 Dec;2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251. Epub 2023 Oct 22. NEJM Evid. 2023. PMID: 38320501 Clinical Trial.
MRI-Targeted Prostate Biopsy Introduces Grade Inflation and Overtreatment.
Batouche AO, Czeizler E, Lehto TP, Erickson A, Shadbahr T, Laajala TD, Pohjonen J, Vickers AJ, Mirtti T, Rannikko AS. Batouche AO, et al. Among authors: rannikko as. medRxiv [Preprint]. 2024 Jan 10:2024.01.10.24300922. doi: 10.1101/2024.01.10.24300922. medRxiv. 2024. PMID: 38260466 Free PMC article. Preprint.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND. Freedland SJ, et al. Among authors: rannikko a. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
137 results